ARCH-backed George Church spinout shuts down after gene therapy tech struggles in animal models
Harvard bioengineer George Church likes students with big ideas and he likes to help them make those ideas a reality, serving as a co-founder or advisor on dozens of the zany and ambitious startups to spin out of his lab.
But not all ideas are quite ready to change medicine.
Ally Therapeutics, a gene therapy biotech that launched out of Church’s lab in 2018 and later raised seed cash from ARCH and other blue-chip VCs, shut down earlier this year, board member Bob More confirmed in an email.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.